Secondary somatic mutations in RAD51C and RAD51D genes restoring the reading frame of the proteins have been reported in post-progression tumor samples obtained from patients participating in ARIEL2 Part1 clinical trial, in which patients with platinum-sensitive, relapsing tumor were treated with the PARP inhibitor rucaparib. This evidence concerns the gene RAD51D and neoplasm.